Clinical and Experimental Ophthalmology Conversations
A recent systematic review and meta-analysis of studies on dominant optic atrophy found that visual acuity was the only biomarker with longitudinal data, and its rate of change did not differ significantly from zero. These findings highlight a critical gap in the field - robust, sensitive biomarkers capable of capturing disease progression are lacking. Identifying alternative structural, functional or molecular biomarkers will be essential for designing and validating future therapeutic clinical trials in dominant optic atrophy.
3 afleveringen
Reacties
0Wees de eerste die een reactie plaatst
Meld je nu aan en word lid van de Clinical and Experimental Ophthalmology Conversations community!